Onartuzumab

Neoplasms

Hoffmann-La Rochemonoclonal_antibodyPhase 3Dormant

B

59/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 56/ 100
Competitive Position: 65/ 100

Competitive context

928 Active assets in the Neoplasms cohort.

Asset / Sponsor	Phase	Rating
PANITUMUMAB Astellas Pharma Inc	Phase 2	BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM Sanofi	Phase 4	BB
Relatlimab Bristol-Myers Squibb	Phase 2	BB
DINITROGEN MONOXIDE Medical College of Wisconsin	Phase 4	BB
Bxcl501 Medical College of Wisconsin	Phase 4	BB

View all 50 →

Same molecule, other indications

Onartuzumab is also rated in:

non-small cell lung carcinomaDormant

BBB

Indicative ·

74 / 100

non-small cell lung carcinomaDormant

CCC

Indicative ·

52 / 100

glioblastomaDormant

CCC

Indicative ·

51 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.